Bris­tol My­ers, As­traZeneca strike $510M set­tle­ment on PD-L1, CT­LA-4 patent law­suits

As­traZeneca shelled out $510 mil­lion to set­tle patent law­suits around its PD-L1 and CT­LA-4 drugs, hand­ing Bris­tol My­ers Squibb an­oth­er win in its quest to as­sert pi­o­neer sta­tus with its check­point fran­chis­es.

A judge in the US Dis­trict Court in Delaware of­fi­cial­ly ap­proved the com­pa­nies’ joint stip­u­la­tion to dis­miss the case on Mon­day, ac­cord­ing to court doc­u­ments. But the set­tle­ment was struck ear­li­er in Ju­ly: As­traZeneca dis­closed in its sec­ond-quar­ter earn­ings re­port that it en­tered a glob­al set­tle­ment that “re­solves all patent dis­putes re­lat­ing to Imfinzi and Imju­do be­tween the com­pa­nies.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER